Comparative Pharmacology
Head-to-head clinical analysis: AZILSARTAN MEDOXOMIL versus BYVALSON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZILSARTAN MEDOXOMIL versus BYVALSON.
AZILSARTAN MEDOXOMIL vs BYVALSON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin II receptor blocker (ARB) that selectively inhibits angiotensin II binding to AT1 receptors, reducing vasoconstriction, aldosterone secretion, and sympathetic activity.
Valsartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting angiotensin II-mediated vasoconstriction and aldosterone secretion. It also reduces blood pressure and causes vasodilation.
40 mg orally once daily. May increase to 80 mg once daily if needed.
160 mg orally once daily.
None Documented
None Documented
Terminal half-life approximately 11 hours; supports once-daily dosing with sustained antihypertensive effect over 24 hours.
Clinical Note
moderateAzilsartan medoxomil + Benzydamine
"The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Benzydamine."
Clinical Note
moderateAzilsartan medoxomil + Droxicam
"The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Droxicam."
Clinical Note
moderateAzilsartan medoxomil + Loxoprofen
"The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Loxoprofen."
Clinical Note
moderateTerminal half-life 10-12 hours; allows once-daily dosing; extended in severe renal impairment (up to 20 hours)
Biliary/fecal (55% unchanged), renal (42% as inactive metabolites, <1% unchanged)
Renal: 60% unchanged; Biliary/Fecal: 40% as metabolites; total clearance ~30 L/h
Category C
Category C
Angiotensin II Receptor Blocker
Angiotensin II Receptor Blocker
Azilsartan medoxomil + Clonixin
"The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Clonixin."